The development of drugs for brain-related conditions is not an efficient process. A key reason for this is a lack of preclinical tests that accurately predict drug efficacy and detect unwanted side effects. But now, researchers have developed a new preclinical approach that they hope can be used alongside current strategies to guide more efficient drug development for brain-related conditions.